Journal
Biology of blood and marrow transplantation
Publication Date
2018
Volume
24
Issue
6
Inclusive Pages
1187-1195
Document Type
Open Access Publication
DOI
10.1016/j.bbmt.2018.01.039
Rights and Permissions
Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant. 2018 Jun;24(6):1187-1195. doi: 10.1016/j.bbmt.2018.01.039 © 2018 American Society for Blood and Marrow Transplantation. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Micallef, Ivana N.; Stiff, Patrick J.; Nademanee, Auayporn P.; Maziarz, Richard T.; Horwitz, Mitchell E.; Stadtmauer, Edward A.; Kaufman, Jonathan L.; McCarty, John M.; Vargo, Rita; Cheverton, Peter D.; Struijs, Martin; Bolwell, Brian; and DiPersio, John F., "Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: Long-term follow-up report." Biology of blood and marrow transplantation. 24, 6. 1187-1195. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7874
Figure S1. Triple-endpoint survival in patients with NHL stratified by treatment group.
1-s2.0-S1083879118300569-mmc2.pdf (106 kB)
Figure S2. Triple-endpoint survival in patients with MM stratified by treatment group.
1-s2.0-S1083879118300569-mmc3.docx (14 kB)
Table S1. Demographics and baseline characteristics of the primary NHL population enrolled in Study 3101 stratified by treatment group*.
1-s2.0-S1083879118300569-mmc4.docx (14 kB)
Table S2. Demographic data and baseline characteristics of the primary MM population enrolled in Study 3102 stratified by treatment group‡.
